Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
28 Juin 2013 - 10:36PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a
biopharmaceutical company focused on developing and commercializing
an inhaled anti-infective to treat patients battling serious lung
diseases that are often life-threatening, today announced that the
Company will report top-line results from its European and Canadian
Phase 3 study of ARIKACE® (liposomal amikacin for inhalation) to
treat cystic fibrosis patients with Pseudomonas aeruginosa lung
infections on Monday, July 1, 2013 at 7:00 a.m. Eastern time.
Insmed management will hold a conference call to discuss the
results and answer questions on Monday, July 1, 2013 beginning at
8:00 a.m. Eastern time. Shareholders and other interested parties
may participate in the call by dialing 888-803-5993 (domestic) or
706-634-5454 (international) and referencing conference ID number
13711485. The press release and several data slides will be posted
at 7:15 a.m. Eastern time on July 1, 2013 on the homepage of the
Company's website at www.insmed.com. The call will also be webcast
live and archived on the Company's website at
http://investor.insmed.com/events.cfm.
A replay of the conference call will be accessible two hours
after its completion through July 15, 2013, by dialing 855-859-2056
(domestic) or 404-537-3406 (international) and referencing
conference ID number 13711485. The call will also be archived for
90 days on the Company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE®, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections and patients
with non-tuberculous mycobacteria (NTM) lung infections. For more
information, please visit http://www.insmed.com.
Forward-Looking Statements
This release contains forward-looking statements that are made
pursuant to provisions of Section 21E of the Securities Exchange
Act of 1934. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose"
and similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of results of preclinical studies and clinical trials and
preclinical and clinical data and the anticipated benefits of
Insmed's products, and to the Company's cash position and financing
needs, constitute forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. Such risks and
uncertainties include, without limitation, failure or delay of U.S.
Food and Drug Administration and other regulatory reviews and
approvals, competitive developments affecting the Company's product
candidates, delays in product development or clinical trials or
other studies, patent disputes and other intellectual property
developments relating to the Company's product candidates,
unexpected regulatory actions, delays or requests, the failure of
clinical trials or other studies or results of clinical trials or
other studies that do not meet expectations, inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, inability to make product
candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations.
Investor Relations Contacts: LHA Anne Marie Fields Senior
Vice President 212-838-3777 afields@lhai.com Bruce Voss Managing
Director 310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024